1. Home
  2. KALV vs DPG Comparison

KALV vs DPG Comparison

Compare KALV & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • DPG
  • Stock Information
  • Founded
  • KALV N/A
  • DPG 2011
  • Country
  • KALV United States
  • DPG United States
  • Employees
  • KALV N/A
  • DPG N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • DPG Trusts Except Educational Religious and Charitable
  • Sector
  • KALV Health Care
  • DPG Finance
  • Exchange
  • KALV Nasdaq
  • DPG Nasdaq
  • Market Cap
  • KALV 523.1M
  • DPG 442.5M
  • IPO Year
  • KALV N/A
  • DPG N/A
  • Fundamental
  • Price
  • KALV $11.18
  • DPG $11.51
  • Analyst Decision
  • KALV Strong Buy
  • DPG
  • Analyst Count
  • KALV 4
  • DPG 0
  • Target Price
  • KALV $29.00
  • DPG N/A
  • AVG Volume (30 Days)
  • KALV 247.5K
  • DPG 150.1K
  • Earning Date
  • KALV 12-05-2024
  • DPG 01-01-0001
  • Dividend Yield
  • KALV N/A
  • DPG 9.09%
  • EPS Growth
  • KALV N/A
  • DPG N/A
  • EPS
  • KALV N/A
  • DPG N/A
  • Revenue
  • KALV N/A
  • DPG N/A
  • Revenue This Year
  • KALV N/A
  • DPG N/A
  • Revenue Next Year
  • KALV $539.64
  • DPG N/A
  • P/E Ratio
  • KALV N/A
  • DPG N/A
  • Revenue Growth
  • KALV N/A
  • DPG N/A
  • 52 Week Low
  • KALV $7.21
  • DPG $7.90
  • 52 Week High
  • KALV $16.88
  • DPG $13.58
  • Technical
  • Relative Strength Index (RSI)
  • KALV 46.78
  • DPG 49.64
  • Support Level
  • KALV $10.78
  • DPG $11.11
  • Resistance Level
  • KALV $12.12
  • DPG $11.54
  • Average True Range (ATR)
  • KALV 0.72
  • DPG 0.16
  • MACD
  • KALV -0.07
  • DPG -0.03
  • Stochastic Oscillator
  • KALV 41.20
  • DPG 51.43

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting primarily from a high level of current income, with an emphasis on providing tax-advantaged dividend income.

Share on Social Networks: